<DOC>
	<DOCNO>NCT01954589</DOCNO>
	<brief_summary>A study ACT-462206 evaluate tolerability , safety , pharmacokinetics , pharmacodynamic ascend single dos ACT-462206 , novel dual orexin receptor antagonist healthy male subject .</brief_summary>
	<brief_title>Single-ascending Dose Study Investigate Tolerability , Safety , Pharmacokinetics , Pharmacodynamics ACT-462206</brief_title>
	<detailed_description>Each dose level investigate new group eight healthy male subject ( six active drug two placebo ) . Each subject participate one treatment period , exception subject crossover part ( i.e. , almorexant reference group fourth dose level ) , participate two treatment period . At dose level subject active drug ( six ) receive one treatment period ACT-462206 400 mg almorexant ; subject placebo ( two ) receive correspond placebo ( double-dummy ) .</detailed_description>
	<criteria>Inclusion Criteria Healthy male subject age 18 45 year ( inclusive ) screen Hematology , clinical chemistry , urinalysis result deviate normal range clinically relevant extent screen No clinically significant finding physical examination screen Body mass index 18.0 28.0 kg/m^2 ( inclusive ) screen Systolic blood pressure 100145 mmHg , diastolic blood pressure 5090 mmHg , heart rate 4590 beat per minute ( inclusive ) measure screen dominant arm ( dominant arm writing arm ) 5 min supine position 12lead electrocardiogram without clinically relevant abnormality supine position screen Negative result urine drug screen screen Ability communicate well investigator local language , understand comply requirement study . Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction Veins unsuitable intravenous puncture either arm ( e.g. , vein difficult locate , access puncture , vein tendency rupture puncture ) Treatment prescribe medication ( include vaccine ) overthecounter medication ( include herbal medicine St John 's Wort ) within 2 week prior ( first ) study drug administration Treatment another investigational drug within 3 month prior screen participate four investigational drug study within 1 year prior screen History clinical evidence alcoholism drug abuse within 3year period prior screen History clinical evidence disease , and/or existence surgical medical condition , might interfere absorption , distribution , metabolism excretion study drug Excessive caffeine consumption , define â‰¥ 800 mg per day screen caffeine ) Smoking within 3 month prior screen inability refrain smoke course study Loss 250 mL blood , equivalent amount plasma , within 3 month prior screen Positive result hepatitis serology , except vaccinated subject subject past resolve hepatitis , screen Positive result human immunodeficiency virus serology screen Known hypersensitivity excipients drug formulation Modified Swiss Narcolepsy Scale total score &lt; 0 history narcolepsy cataplexy Any circumstance condition , , opinion investigator , might affect full participation study compliance protocol Legal incapacity limit legal capacity screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>ACT-462206</keyword>
	<keyword>Selective dual orexin receptor antagonist</keyword>
</DOC>